

Intelence® (etravirine) - Expanded indication

- On July 16, 2018, the FDA announced the approval of Janssen's Intelence (etravirine), in combination with other antiretroviral (ARV) agents, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in ARV treatment-experienced patients ages 2 years and older, who have evidence of viral replication and HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor and other ARV agents.
 - Previously, Intelence was only approved for patients ≥ 6 years.
- The expanded indication for Intelence was demonstrated in a study evaluating the
 pharmacokinetics, safety, tolerability, and efficacy of Intelence in 20 ARV treatment-experienced
 HIV-1 infected pediatric subjects 2 years to less than 6 years of age. Virologic response, defined as
 achieving plasma viral load < 400 HIV-1 RNA copies/mL, was evaluated.
 - At week 24, the proportion of subjects with < 400 HIV-1 RNA copies/mL was 88%.</p>
 - In addition, the use of Intelence in pediatric patients 2 years to less than 18 years of age is supported by evidence from adequate and well-controlled studies in adults.
- The most common adverse drug reactions (≥ 2%) with Intelence use in pediatric patients were rash and diarrhea.
- The recommended dose of Intelence for pediatric patients 2 years to less than 18 years of age and weighing at least 10 kg is based on body weight, not exceeding the recommended adult dose taken orally following a meal as follows:

Body Weight (kg)	Dose
≥ 10 kg to < 20 kg	100 mg twice daily
≥ 20 kg to < 25 kg	125 mg twice daily
≥ 25 kg to < 30 kg	150 mg twice daily
≥ 30 kg	200 mg twice daily

Consult the Intelence drug label for adult dosing recommendations.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.